Furthermore, the biology of the underlying cancer can influence the occurrence of VTE, especially in patients with ROS proto-oncogene 1 (ROS1) fusion, anaplastic lymphoma kinase (ALK) fusion, and Kirsten rat sarcoma viral oncogene (KRAS) mutation [19,20]. Here, ALK is linked to cancer.